Osumi T - Search Results

1

Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased α-Catenin.

Shukla S, Osumi T, Al-Toubat M, Serrano S, Singh PK, Mietzsch M, McKenna R, Chardon-Robles J, Krishnan S, Balaji KC. Shukla S, et al. Among authors: osumi t. Prostate. 2025 Feb;85(2):156-164. doi: 10.1002/pros.24812. Epub 2024 Oct 20. Prostate. 2025. PMID: 39428693

2

3JC48-3 (methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth.

Shukla S, Fletcher S, Chauhan J, Chalfant V, Riveros C, Mackeyev Y, Singh PK, Krishnan S, Osumi T, Balaji KC. Shukla S, et al. Among authors: osumi t. Cancer Gene Ther. 2022 Nov;29(11):1550-1557. doi: 10.1038/s41417-022-00455-4. Epub 2022 Apr 19. Cancer Gene Ther. 2022. PMID: 35440696

3

The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth.

Shukla S, Riveros C, Al-Toubat M, Chardon-Robles J, Osumi T, Serrano S, Kase AM, Petit JL, Meurice N, Gleba J, Copland JA 3rd, Chauhan J, Fletcher S, Balaji KC. Shukla S, et al. Among authors: osumi t. Cancers (Basel). 2023 Jul 28;15(15):3851. doi: 10.3390/cancers15153851. Cancers (Basel). 2023. PMID: 37568667 Free PMC article.

4

Long-term Use of Ibrutinib in Japanese Patients with Steroid Dependent/Refractory cGVHD: Final Analysis of Multicenter Study.

Toyosaki M, Doki N, Shiratori S, Osumi T, Okada M, Kawakita T, Sawa M, Ishikawa T, Ueda Y, Hatayama T, Yoshinari N, Fujikawa E. Toyosaki M, et al. Among authors: osumi t. Blood Cell Ther. 2023 Nov 10;6(4):104-113. doi: 10.31547/bct-2023-010. eCollection 2023 Nov 25. Blood Cell Ther. 2023. PMID: 38149026 Free PMC article.

5

Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.

Mori T, Osumi T, Kada A, Ohki K, Koga Y, Fukano R, Fujita N, Mitsui T, Mori T, Saito AM, Nakazawa A, Kobayashi R, Sekimizu M. Mori T, et al. Among authors: osumi t. Eur J Haematol. 2024 Apr;112(4):585-593. doi: 10.1111/ejh.14148. Epub 2023 Dec 19. Eur J Haematol. 2024. PMID: 38112205 Clinical Trial.

6

A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs.

Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H, Hirose M. Thomsen M, et al. Among authors: osumi t. Microbiome. 2023 Oct 21;11(1):232. doi: 10.1186/s40168-023-01671-2. Microbiome. 2023. PMID: 37864204 Free PMC article.

7

Prevalence of pathogenic variants in cancer-predisposing genes in second cancer after childhood solid cancers.

Yoshida M, Nakabayashi K, Yang W, Sato-Otsubo A, Tsujimoto SI, Ogata-Kawata H, Kawai T, Ishiwata K, Sakamoto M, Okamura K, Yoshida K, Shirai R, Osumi T, Kiyotani C, Shioda Y, Terashima K, Ishimaru S, Yuza Y, Takagi M, Arakawa Y, Imamura T, Hasegawa D, Inoue A, Yoshioka T, Ito S, Tomizawa D, Koh K, Matsumoto K, Kiyokawa N, Ogawa S, Manabe A, Niwa A, Hata K, Yang JJ, Kato M. Yoshida M, et al. Among authors: osumi t. Cancer Med. 2023 May;12(10):11264-11273. doi: 10.1002/cam4.5835. Epub 2023 Apr 6. Cancer Med. 2023. PMID: 37021926 Free PMC article.

8

Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.

Shirai R, Osumi T, Keino D, Nakabayashi K, Uchiyama T, Sekiguchi M, Hiwatari M, Yoshida M, Yoshida K, Yamada Y, Tomizawa D, Takae S, Kiyokawa N, Matsumoto K, Yoshioka T, Hata K, Hori T, Suzuki N, Kato M. Shirai R, et al. Among authors: osumi t. Int J Hematol. 2023 Jun;117(6):910-918. doi: 10.1007/s12185-023-03566-2. Epub 2023 Mar 3. Int J Hematol. 2023. PMID: 36867356 Free PMC article.

9

Non-germinal center B-cell subtype of pediatric diffuse large B-cell lymphoma in Japan: A retrospective cohort study.

Hori D, Kobayashi R, Nakazawa A, Iwafuchi H, Klapper W, Osumi T, Ohk K, Sekimizu M. Hori D, et al. Among authors: osumi t. Pediatr Blood Cancer. 2023 May;70(5):e30279. doi: 10.1002/pbc.30279. Epub 2023 Mar 1. Pediatr Blood Cancer. 2023. PMID: 36860130

10

Successful hematopoietic stem cell transplantation with reduced dose of busulfan for Omenn syndrome.

Matsukawa Y, Isshiki K, Osumi T, Fujiyama S, Fukushima H, Uchiyama T, Yamada M, Deguchi T, Imadome KI, Matsumoto K, Tomizawa D, Takada H, Onodera M, Kato M. Matsukawa Y, et al. Among authors: osumi t. Blood Cell Ther. 2022 May 27;5(3):75-78. doi: 10.31547/bct-2021-021. eCollection 2022 Aug 25. Blood Cell Ther. 2022. PMID: 36712554 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

313 results

Search Page

Filters